Navigation Links
Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
Date:5/31/2013

WASHINGTON, May 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corporate presentation at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2013 at 2:30 p.m. Eastern Time.

The presentation at the Jefferies Global Healthcare Conference will be available live on Vanda's corporate website, where it also will be archived for 30 days.  To access the presentation, go to Vanda's website at www.vandapharma.com and click on the Presentations tab on the Investor Relations page.  Please connect to the website several minutes prior to the start of the live presentation.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Company Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
2. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
3. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
4. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
5. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
6. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
7. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
9. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
10. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
11. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... clinical studies evaluating potential new medicines in the ... upcoming 2014 European Society of Medical Oncology (ESMO) ... Spain . Data being presented include results ... and efficacy of veliparib (ABT-888), a poly (adenosine ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... and NEW YORK , ... (OTCBB: ACCP), has signed an exclusive, global license ... development and commercialization of its proprietary plasma fractionation ... management team and its intention to strategically refocus ... and its plans to pursue a national listing ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... SILVER SPRING, Md., March 25, 2011 The U.S. Food ... patients with late-stage (metastatic) melanoma, the most dangerous type ... ) Melanoma is the leading cause ... cases of melanoma were diagnosed in the United States ...
... CoreLab Partners, Inc , the global entity resulting ... is set to attend and actively participate in several ... two weeks. "The legacy of our organization ... physicians, scientists and operational personnel have provided to the ...
Cached Medicine Technology:FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 2FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 3CoreLab Partners Collaborates at Worldwide Industry Conferences 2
(Date:9/22/2014)... 2014 PreDiabetes Centers , a ... with companies to help employees learn their risk for ... as part of a collaboration with the American Diabetes ... , PreDiabetes Centers Medical Director Alan Hopkins, MD, ... Austin on Tuesday, October 21st to discuss the epidemic ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... have known that bacterial pneumonia can raise your risk of ... actually invade and kill heart cells, increasing the chances of ... scientists report. In mice, monkeys and human heart ... the bacteria, and they tried a vaccine that might one ...
(Date:9/22/2014)... 2014 At the 10th Clinton ... Nutrition Partnership (SNP) announced the successful launch of ... Cardiovascular Risk Reduction Program for Women. The announcement ... mitigate their risk of heart disease through a ... plan for addressing significant global challenges made by ...
(Date:9/22/2014)... 2014 TweetMyJobs, a global ... today an agreement with HealthcareSource, the leading ... healthcare industry. The agreement gives HealthcareSource clients ... recruiting solutions directly from within HealthcareSource Position ... healthcare organizations. The partnership provides TweetMyJobs additional ...
(Date:9/22/2014)... MAINE AND BOSTON -- In a collaboration that ... advance cancer research and patient care and accelerate ... Beth Israel Deaconess Medical Center (BIDMC) have established ... institutions, presidents announced today. , A recently signed ... Center to establish a comprehensive relationship in the ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 2Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 2Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 3Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 4Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3
... could help prevent complications for pregnant women with the ... the 20th week of pregnancy and is characterized by ... the urine. In severe cases it can lead to ... the mother to suffer a series of potentially fatal ...
... embryo transfer instead of a double embryo transfer during ... births without substantially lowering live births, // according to ... than 36 and compared the two approaches of in ... at least one live birth and rates of multiple ...
... nearly 15 million people worldwide. Problems with a ... sneezing, laughing, or lifting heavy objects. Austrian researchers ... with their own stem cells, which they say ... involves removing stem cells from a patient's arm, ...
... that stem cell therapy is effective in treating pigs ... cells from one pig's bone marrow and injecting them ... heart's function to its original condition. ,Researchers studied ... and half of them received therapy. They found injecting ...
... According to a recent study researchers say autistic boys with ... suffering from a language-related disorder known as Specific Language Impairment ... specialists better understand autism and how to choose the best ... MRI scans to look at Broca’s area -- a key ...
... new study the healthiest environment for your child at bedtime ... at night may put children at risk for leukemia.// ... night workers and an increased risk for breast cancer, further ... factor for leukemia. ,Researchers have determined that light at ...
Cached Medicine News:
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Medicine Products: